1 / 52

Pharmacology Review…Intro?

Pharmacology Review…Intro?. Pharmacokinetics Pharmacodynamics Drug Interactions Tolerance. Pharmacokinetics. Pharm - drug , kinetics - movement The interaction of drugs with the body

Download Presentation

Pharmacology Review…Intro?

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Pharmacology Review…Intro? • Pharmacokinetics • Pharmacodynamics • Drug Interactions • Tolerance

  2. Pharmacokinetics • Pharm - drug, kinetics - movement • The interaction of drugs with the body • Primarily: Absorption, distribution and elimination of drugs and the factors that affect this process(s).

  3. Absorption Factors affecting absorption of drugs • Route of Administration • Physical properties of the drug and the tissues (organs)

  4. AbsorptionFactors affecting absorption of drugs Routes of Administration • Topical: Skin & Eyes • Oral: Gastrointestinal & Sublingual • Rectal • Nasal • Inhalational (Lungs) • Parenteral: Intra- venous or muscular (IV, IM) • Intrathecal

  5. AbsorptionFactors affecting absorption of drugs Physical properties of the drug and the tissues (organs) • Solubility of the drug; solubility coefficient • Lipophilic versus Hydrophilic • pH of the solvent (drug is the solute) • Degree of Ionization (pKa) • Concentration of the drug

  6. AbsorptionFactors affecting absorption of drugs Physical properties of the drug and the tissues (organs) • Permiability of the tissue and size of the drug molecule • Surface area of the tissue/organ • Blood supply (vasculature) of the route tissue/organ

  7. AbsorptionFactors affecting absorption of drugs Routes

  8. AbsorptionFactors affecting absorption of drugs Liver Circulation Liver GI Tract - - - - IV

  9. AbsorptionFactors affecting absorption of drugs Routes of Administration • Topical: Skin & Eyes • Oral: Gastrointestinal & Sublingual • Rectal • Nasal • Inhalational (Lungs) • Parenteral: Intra- venous or muscular (IV, IM) • Intrathecal

  10. Distribution • Most drugs are not distributed evenly throughout the body • Circulatory system is the primary route for distribution • Physico-chemical properties of the drug will determine its distribution

  11. DistributionFactors that affect Distribution • Solubility (Polarity & Lipophilicity) • distribution in water versus fat compartments • Binding to serum albumin proteins • pKa • Molecular size

  12. DistributionVolume of Distribution • Relationship of Dose to Drug Concentration depends upon the Volume • Drug concentrations are measured in blood (serum) only, but drugs are usually distributed into other compartments as well C = D V

  13. DistributionVolume of Distribution • Volume of Distribution therefore refers to the apparent distribution from blood alone • Blood has a very high water content • Blood represents only about 6% of the total body water. C = D Vd

  14. DistributionVolume of Distribution C = D Vd • Volume of Blood, Interstitial Fluid and Tissue Fluid = Total Body Water • Plasma = 2.8 L (4%) • Interstitial Fluid = 9.2 L (12 L; 20%) • Intracellular Fluid = 30L (42 L; 60%) • TBW: Males = 60-70 % / Females 50-60 %

  15. DistributionVolume of Distribution C = D Vd • A drug which is poorly distributed beyond the blood will have a lower Vd than a drug which distributes throughout the body, which will have a lower Vd from a drug that distributes in fat • Barbiturates : Vd << 1 L/kg • Ethanol : Vd = 0.53 L/kg • THC: Vd = 4 to 14 L/kg

  16. DistributionFactors that affect Distribution • Solubility (Polarity & Lipophilicity) • distribution in water versus fat compartments • fat soluble drugs pass through membranes and low water tissues more rapidly • may be distributed/stored in fat • may be poorly taken up in the blood/need a carrier

  17. DistributionFactors that affect Distribution • Binding to serum albumin proteins • Drug distribution to other compartments is reduced and slowed • eg. Barbiturates. ~ 99% protein bound. • Apparent distribution is in 2.8 L; blood concentrations are much higher than target tissues (eg. Brain cells).

  18. DistributionFactors that affect Distribution • Solubility (Polarity & Lipophilicity) • distribution in water versus fat compartments • Binding to serum albumin proteins • pKa • Molecular size

  19. DistributionFactors that affect Distribution • pKa (Ionization) • CH3-CH3-COOH CH3-CH3-COO- • Ionized forms are more polar, thus retarded by cell membranes, but more soluble in water

  20. DistributionFactors that affect Distribution • Molecular Size • Small molecules (Ethanol) CH3-CH20H pass rapidly through cell membranes without uptake mechanisms • Larger molecules (Mannitol) are retarded and may be excluded from some compartments

  21. Elimination • Definition • Removal of the drug by either • metabolism (conversion) to another subtance • excretion of the drug in unchanged form

  22. EliminationRoutes • Liver • Kidney • Lungs • Sweat • Hair

  23. EliminationLiver • Major site of metabolism • Enzymatic • Type I - modification of the drug by hydrolysis, methylation, oxidation etc. • Type II - conjugation to a large polar molecule (eg glucuronidation)

  24. EliminationLiver • “Goal” to make the drug more • soluble in water (excretion via Kidneys) • soluble in bile (excretion via feces). • Liver takes 100% of blood from stomach and intestines and 40% total circulation • Major metabolic and de-toxifying organ

  25. EliminationKidneys • Major site of water and salt balance and nitrogen (urea) elimination. • Filters the blood • Polar drugs and metabolites will pass into the urine with water • Ionization status will also affect excretion

  26. Minor Routes of Elimination • Lungs • Drug must be volatile (eg. Inhaled anaesthetics and alcohols) • Sweat • polar, water soluble drugs will pass into the sweat • Hair • deposition from growing end, drugs sequestered in dead hair cells outside of body

  27. Elimination Kinetics • Enzymatic elimination of drugs primarily First Order Kinetics (Michaelis-Menton) C =Coe-kt • Elimination half life t 1/2 = 0.693/k

  28. Elimination Kinetics (Michaelis-Menton) Actual change in concentration over time Logarithimic change in concentration over time

  29. Elimination Kinetics • Elimination is dependent upon concentration, but almost 97% will be eliminated after 5 half-lives Initial concentration 1 mg% One half life 0.5 mg% Two half lives 0.25 mg% Three half lives 0.125 mg% Four half lives 0.0625 mg% Five half lives 0.03125 mg% or 0.96875 mg% (97%) eliminated

  30. Non-Enzymatic Breakdown • Some drugs are unstable at physiological pH or in either acid or base conditions • These drugs will breakdown to products over time (the equivalent of metabolism and elimination) • The problem for Forensic Toxicology is that these processes can occur postmortem and especially in-vitro.

  31. Non-Enzymatic BreakdownExample Cocaine • Cocaine is metabolized to ecgonine methylester (EME) by an esterase in the blood (pseudocholinesterase) • Cocaine also breaks down over time to Benzoylecgonine (BE), especially at physiological and alkaline pH

  32. Non-Enzymatic BreakdownExample Cocaine • Preservatives (chemicals which bind enzymes and prevent postmortem enzymatic changes and tissue breakdown) will stop the metabolism of cocaine to EME, but not the breakdown of cocaine to BE. • Thus some or all of the BE detected in a sample may have been cocaine prior to death

  33. Steady State • At therapeutic concentrations drugs taken over a period of time attain Css Steady state concentration Mean Css Blood concentration Time

  34. Kinetics in Overdose • Absorption, Distribution and especially elimination of drugs can change in overdose • Large amounts of drugs in the stomach cause ‘concretions’ which reduces absorption

  35. Kinetics in Overdose • Distribution may be altered, for example protein binding sites in the blood may become saturated - Vd may change • Elimination kinetics may change; often dramatically, when enzymes become saturated and enter zero-order kinetics, an increase in dose will now lead too much greater blood concentrations with an altered half-life

  36. PharmacodynamicsThe Site of Drug Action • Agonist -a molecule that ‘fits’ a receptor by either its spacial and/or ionic properties • Antagonist - a molecule which blocks a receptor by either binding to a non-activating site or physically blocking the site (or causing only very weak activity). • Most drugs mimic natural agonists

  37. PharmacodynamicsThe Site of Drug Action • Lock and Key Natural Agonist Antagonist Drug Agonist

  38. PharmacodynamicsThe Site of Drug Action • Antagonist effects • Blocking metabolism - re-uptake inhibitors allow the natural molecule (cocaine - dopamine; Prozac etc - serotonin) to remain longer at the site of action • May have beneficial or detrimental effects • May also act as an antidote

  39. PharmacodynamicsThe Site of Drug Action • Some drug families are based on receptor binding eg. Opioids- related to morphine; all opioids bind to one or more of the three classes of opioid receptors • Receptors may activate inhibitory pathways; thus agonists may produce inhibitory responses while antagonists may produce excitatory responses (e.g. GABA pathways).

  40. Drug - Drug InteractionsKinetic Effects • Drugs may be metabolised by the same enzyme system(s). • Consequence: Induction or inhibition of metabolic pathways by one drug resulting in increasing or decreasing blood concentrations of the other drug (Has implications for the drug with the lowest therapeutic index/greatest disease impact).

  41. Drug - Drug InteractionsExample Warfarin • Warfarin is taken as an anticoagulant to combat thrombosis (blood clots) which may break free and damage the heart or lungs. • Warfarin is highly protein bound • Warfarin is metabolised by P450 enzyme system (more about this later).

  42. Drug - Drug InteractionsExample Warfarin • Phenobarbital is also highly protein bound and induces the P450 system. • Consequence of someone on warfarin who takes a course of phenobarbital: • Increased free warfarin offset by increased metabolism; net result is increased dose of warfarin needed to achieve anticoagulation. • If dose not lowered at end of phenobarbital treatment, bleeding due to warfarin may result

  43. Drug - Drug InteractionsKinetic Effects • Drug Interactions may also be beneficial, e.g. probenecid blocks movement of penicillin into the urine resulting in higher blood concentrations at lower doses and more effective antibiotic treatment.

  44. Drug - Drug InteractionsTarget Effects • Drugs may have similar (synergistic) effects (e.g. sedation) which may be additive (similar recptors) or supra-additive (two or more targets) or infra-additive (similar receptors; agonist and antagonist) A+B = C A+B > C A+B < A or B

  45. Drug - Drug InteractionsPharmacokinetics • Absorption • Chemical incompatability of two drugs • Prevention of absorption or delay (e.g. decreased gastric motility by opioids) • Distribution • Changes in protein binding • Inhibition in Liver uptake • Change in circulatory flow

  46. Drug - Drug InteractionsPharmacokinetics • Elimination • Enzyme Induction • Enzyme inhibition or competition • Inhibition of recirculation from the bile • Changes in Renal processes • acidic urine facilitates the uptake of bases (and vice versa) into the urine • Reabsorption of some drugs back into the circulation may be blocked

  47. Tolerance • Two primary aspects of tolerance are Metabolic and Functional • Metabolic (primarily hepatic). • Functional (CNS)

  48. Metabolic Dispositional Kinetic Primarily Liver Can involve all drugs Change in [blood] enzyme induction no abstinance (withdrawl) syndrome Functional CNS Dynamic (receptor) Brain CNS drugs only No Change in [blood] learning-like/change in excitation status abstinance syndrome Tolerance

  49. Cross tolerance for drugs using the same Tolerance level is moderate (up to 35% increase in dose) Cross tolerance for drugs with the same effect Tolerance level is high (up to 200% increase in dose) Tolerance

  50. ToleranceStimulants • Functional tolerance develops rapidly and large increases in dose can occur over one drug session e.g. crack cocaine binges • however metabolic tolerance dose not develop as rapidly; deaths due to non-CNS effects, especially cardiac or vascular and/or thermoregulatory causes are common.

More Related